@article{082dec34015c4ae88fb8921345ca0185,
title = "Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia",
abstract = "Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP). We explored to which extent TMP/SMX influenced methotrexate (MTX)/6-mercaptopurine (6MP) dosage, myelosuppression, and event-free survival (EFS) during maintenance therapy. Of 447 study patients treated by the NOPHO ALL92 protocol, 120 patients received TMP/SMX continuously for 2-7 d/wk (TMP/SMX(2-7) ) and 287 patients never received TMP/SMX (TMP/SMX(never) ). Ten patients (all TMP/SMX(never) ) developed PCP, eight of which occurred within 7 months from the start of maintenance therapy. The TMP/SMX(2-7) group received lower oral 6MP doses than TMP/SMX(never) patients (50.6 vs. 63.9 mg/m(2) /d; P",
keywords = "6-Mercaptopurine, Administration, Oral, Anti-Infective Agents, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Male, Methotrexate, Pneumocystis jirovecii, Pneumonia, Pneumocystis, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Trimethoprim-Sulfamethoxazole Combination",
author = "Mette Levinsen and Diana Shabaneh and Cathrine Bohnstedt and Arja Harila-Saari and Jonsson, {Olafur G} and Jukka Kanerva and Anna Lindblom and Bendik Lund and Andersen, {Louise Elisabeth} and Kjeld Schmiegelow and {Nordic Society of Paediatric Haematology and Oncology (NOPHO)}",
note = "{\textcopyright} 2011 John Wiley & Sons A/S.",
year = "2012",
doi = "10.1111/j.1600-0609.2011.01695.x",
language = "English",
volume = "88",
pages = "78--86",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Munksgaard",
number = "1",
}